| pubmed-article:8391249 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8391249 | lifeskim:mentions | umls-concept:C0019342 | lld:lifeskim |
| pubmed-article:8391249 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8391249 | lifeskim:mentions | umls-concept:C0085979 | lld:lifeskim |
| pubmed-article:8391249 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:8391249 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:8391249 | lifeskim:mentions | umls-concept:C0286079 | lld:lifeskim |
| pubmed-article:8391249 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:8391249 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:8391249 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8391249 | pubmed:dateCreated | 1993-7-28 | lld:pubmed |
| pubmed-article:8391249 | pubmed:abstractText | The nucleoside analogue (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) inhibited the replication of herpes simplex virus (HSV) types 1 and 2 in tissue culture cells at about 1.0 micrograms/ml, whereas Acyclovir (ACV) had an EC50 of about 0.10-0.50 micrograms/ml. The purpose of these studies was to evaluate the efficacy of topically applied HPMPC in animal models of primary and recurrent genital HSV-2 infections. Mice treated with 5%, 1% or 0.5% HPMPC three times daily, beginning 6 or 24 h after virus inoculation had reduced vaginal viral replication regardless of time of initiation of therapy. ACV at 5% also reduced vaginal viral replication, but not as effectively as HPMPC. In primary infection of guinea pigs, therapy with 5% or 1% HPMPC beginning at 24 h but not 72 h significantly altered lesion development. However, 5% HPMPC was highly toxic to guinea pigs. Vaginal viral replication was reduced significantly with either 1% or 0.3% HPMPC initiated at 24 h. In these studies, HPMPC was also more efficacious than 5% ACV. Topical treatment with 1% HPMPC did not reduce the incidence or severity of spontaneous or UV-induced recurrent genital lesions. These results indicate that topical therapy with 1%, 0.5% or 0.3% HPMPC was more effective than 5% ACV in the treatment of primary genital HSV-2 infections of guinea pigs and mice and suggest that HPMPC should be considered for topical use in humans. | lld:pubmed |
| pubmed-article:8391249 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8391249 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8391249 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8391249 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8391249 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8391249 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8391249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8391249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8391249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8391249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8391249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8391249 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8391249 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8391249 | pubmed:month | May | lld:pubmed |
| pubmed-article:8391249 | pubmed:issn | 0166-3542 | lld:pubmed |
| pubmed-article:8391249 | pubmed:author | pubmed-author:KernE RER | lld:pubmed |
| pubmed-article:8391249 | pubmed:author | pubmed-author:StanberryL... | lld:pubmed |
| pubmed-article:8391249 | pubmed:author | pubmed-author:KierA BAB | lld:pubmed |
| pubmed-article:8391249 | pubmed:author | pubmed-author:BoyanCC | lld:pubmed |
| pubmed-article:8391249 | pubmed:author | pubmed-author:VogtP EPE | lld:pubmed |
| pubmed-article:8391249 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8391249 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:8391249 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8391249 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8391249 | pubmed:pagination | 59-72 | lld:pubmed |
| pubmed-article:8391249 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:meshHeading | pubmed-meshheading:8391249-... | lld:pubmed |
| pubmed-article:8391249 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8391249 | pubmed:articleTitle | Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs. | lld:pubmed |
| pubmed-article:8391249 | pubmed:affiliation | Division of Infectious Diseases, Children's Hospital Research Foundation, Cincinnati, Ohio 45220. | lld:pubmed |
| pubmed-article:8391249 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8391249 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8391249 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8391249 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8391249 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8391249 | lld:pubmed |
